The Global Glaucoma Drainage Devices Market to Register

New York, USA, Sept. 29, 2022 (GLOBE NEWSWIRE) — The Global Glaucoma Drainage Devices Market to Register Growth at a Stunning CAGR of 11.95% by 2027 | DelveInsight

The glaucoma drainage devices market is anticipated to boost owing to the rising prevalence of glaucoma diseases, the rising geriatric population susceptible to glaucoma, the rising adoption of surgical treatments for glaucoma, among others.

DelveInsight’s Glaucoma Drainage Devices Market Insights report provides the current and forecast market, forthcoming device innovation, individual leading companies’ market shares, challenges, glaucoma drainage devices market drivers, barriers, and trends, and key glaucoma drainage devices companies in the market. 

Key Takeaways from the Glaucoma Drainage Devices Market Report

• As per DelveInsight estimates, North America is anticipated to dominate the global glaucoma drainage devices market during the forecast period. 
• Notable glaucoma drainage devices companies such as Johnson & Johnson, AbbVie Inc, Alcon Inc, Glaukos Corporation,  Santen Pharmaceutical Co., Ltd,  NovaEye Medical Limited, iSTAR Medical SA, Rheon Medical SA, Advanced Ophthalmic Innovations Pte Ltd, New World Medical Inc, Aurolab, and several others are currently operating in the glaucoma drainage devices market.
• On November 19, 2021, Istar reported the first implant of the Miniject glaucoma device after the CE Mark approval.
• On September 06, 2021, Glaukos submitted the application to the United States FDA for an iStent infinitive device.
• On May 17, 2021, Rheon Medical received the FDA Breakthrough Device Designation for the eyeWatch Technology.
• On March 05, 2020, the FDA approved Allergan’s long-term eye implant for glaucoma.
• Thus, owing to the launch of such devices, there will be a rapid growth observed in the glaucoma drainage devices market during the forecast period.

To read more about the latest highlights related to the glaucoma drainage devices, get a snapshot of the…